Validation Institute Awards CheckMySpot® for Contractual Integrity
Validation Institute is proud to announce that CheckMySpot® has achieved validation for Contractual Integrity. This recognition underscores CheckMySpot's® commitment to transparency and delivering superior results in the healthcare sector.
Founded in 2014, Validation Institute connects, trains, and certifies healthcare organizations that deliver better health value. Their rigorous review process ensures validated programs meet high standards of reliability and credibility. For more information about Validation Institute and its validation process, please visit their website.
CheckMySpot® is dedicated to improving dermatological care by getting skin lesions to definitive treatment sooner while reducing healthcare costs. Their Direct Access Platform™ significantly reduces the average wait time to be seen by a dermatologist, improving survival and surgical outcomes for skin cancers. Additionally, CheckMySpot's® model contract meets Validation Institute standards for transparency, ensuring accurate calculation of promised savings or outcomes. This validation provides purchasers with confidence in the program's impact on patient outcomes and medical costs.
As part of their Credibility Guarantee Program, Validation Institute (VI) offers up to a $100,000 guarantee, demonstrating their confidence in validated solutions.
Quote from CheckMySpot® Leadership: "We are honored to receive this validation from the Validation Institute," said J. Michael Webb, MD FAAD FACMS, Physician Leader of CheckMySpot®. "This recognition reflects our commitment to getting skin lesions to definitive treatment sooner while reducing healthcare costs. Our mission is to provide transparent and effective solutions that save lives and improve surgical outcomes for patients with serious skin lesions.”
“To me, it’s mind-blowing that no one has done this before,” said Al Lewis, Chairman and Validator-in-Chief at VI. “Cancer is the most expensive condition, and skin is both the most common cancer and the most easily detected cancer. Companies that think nothing of paying $2500 for a colonoscopy screen that comes back negative most of the time should jump at the chance to pay a fraction of that for a reading and possible biopsy that comes back positive much of the time.”